{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:21:17Z","timestamp":1782955277164,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012906","name":"Department of Education of Shandong Province","doi-asserted-by":"publisher","award":["SDYJG19212"],"award-info":[{"award-number":["SDYJG19212"]}],"id":[{"id":"10.13039\/100012906","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Schizophrenia is regarded as one of the most severe, disabling, and costly mental illnesses. Hence, early effective prevention and treatment are critical to the prognosis of patients. Amisulpride, a first-line atypical antipsychotic medication that acts as a blocker of the D2 and D3 dopamine receptors, is used in varying doses for the treatment of both positive and negative symptoms of schizophrenia. Reversible amisulpride-induced elevation of the myocardial enzyme spectrum with bradycardia is a rare condition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report a 26-year-old patient diagnosed with first-episode schizophrenia. This patient was treated with amisulpride (400 mg\/d), but no clinical benefits were obtained. Meanwhile, amisulpride caused elevation of the myocardial enzyme spectrum with asymptomatic bradycardia. After stopping the medication, these parameters normalized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We described a rare side reaction of amisulpride. Psychiatrists should take this side effect seriously in the clinical setting. The mechanism of this adverse reaction warrants further investigation and debate. When this side effect occurs during treatment, reducing the dosage of amisulpride and subsequently discontinuing medication, along with monitoring the electrocardiogram and serum myocardial enzymes, may be the most appropriate treatment protocol.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.1037738","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T09:52:31Z","timestamp":1671011551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Amisulpride therapy induced reversible elevation of creatine kinase-MB and bradycardia in schizophrenia"],"prefix":"10.3389","volume":"13","author":[{"given":"Ze-Rui","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Shuo","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British association for psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J Psychopharmacol."},{"key":"B3","unstructured":"179Peking University Medical PressGuidelines for the Prevention and Treatment of Schizophrenia2007"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1176\/appi.ajp.160.8.1413","article-title":"Is regionally selective D2\/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I] epidepride SPET study of amisulpride-treated patients","volume":"160","author":"Bressan","year":"2003","journal-title":"AJP."},{"key":"B5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"AJP."},{"key":"B6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.etp.2005.09.003","article-title":"Cardiac lesions induced by neuroleptic drugs in the rabbit","volume":"57","author":"Belhani","year":"2006","journal-title":"Exp Toxicol Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/YIC.0000000000000420","article-title":"Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data","volume":"37","author":"Qu","year":"2022","journal-title":"Int Clin Psychopharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"815151","DOI":"10.3389\/fphar.2021.815151","article-title":"Characteristics and spectrum of cardiotoxicity induced by various antipsychotics: a real-world study from 2015 to 2020 based on FAERS","volume":"12","author":"He","year":"2022","journal-title":"Front Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.genhosppsych.2013.12.005","article-title":"Amisulpride and symptomatic bradycardia: a case report","volume":"37","author":"Huang","year":"2015","journal-title":"General Hospital Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.pnpbp.2010.10.006","article-title":"Amisulpride therapeutic dose-induced asymptomatic bradycardia","volume":"35","author":"Prikryl","year":"2011","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/appy.12226","article-title":"Asymptomatic bradycardia and hypotension associated with amisulpride: a case report","volume":"8","author":"Su","year":"2016","journal-title":"Asia-Pacific Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00228-009-0773-x","article-title":"Acute rhabdomyolysis during treatment with amisulpride and metformin","volume":"66","author":"Ursini","year":"2010","journal-title":"Eur J Clin Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/s-0035-1549997","article-title":"Reversible amisulpride-induced elevation of creatine kinase (CK): a case series from the German AMSP pharmacovigilance project","volume":"48","author":"Laoutidis","year":"2015","journal-title":"Pharmacopsychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/0003-4819-105-2-221","article-title":"Serum enzyme assays in the diagnosis of acute myocardial infarction recommendations based on a quantitative analysis","volume":"105","author":"Lee","year":"1986","journal-title":"Ann Intern Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00406-018-0959-2","article-title":"Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015","volume":"270","author":"Schneider","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1007\/s00213-014-3764-2","article-title":"Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice","volume":"231","author":"Laoutidis","year":"2014","journal-title":"Psychopharmacology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1941875210386491","article-title":"Neuroleptic malignant syndrome","volume":"1","author":"Berman","year":"2011","journal-title":"The Neurohospitalist."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1161\/01.CIR.93.5.1043","volume":"93","year":"1996","journal-title":"Heart Rate Variabil Circ."},{"key":"B23","unstructured":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1037738\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T09:52:33Z","timestamp":1671011553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.1037738\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":24,"alternative-id":["10.3389\/fpsyt.2022.1037738"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.1037738","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1037738"}}